Targets › PDE1
1 program from 1 company in 1 trial: 1 Phase 2; Neurology; next expected readout Nov 2026.
Open in Phaseline: the race on PDE1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tanta University | Vinpocetine Phosphodiesterase-1 (PDE1) inhibitor that increases dopamine levels and protects dopaminer | PDE1 | Phase 2 | Parkinson Disease | Nov 2026 |
Parkinson Disease (1)
small molecule (1)
Tanta University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.